S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
NASDAQ:CUTR

Cutera Stock Forecast, Price & News

$38.91
+2.86 (+7.93%)
(As of 12/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$36.31
$39.81
50-Day Range
$33.71
$48.92
52-Week Range
$19.88
$60.35
Volume
244,684 shs
Average Volume
199,704 shs
Market Capitalization
$698.71 million
P/E Ratio
94.90
Dividend Yield
N/A
Beta
1.58
30 days | 90 days | 365 days | Advanced Chart
Receive CUTR News and Ratings via Email

Sign-up to receive the latest news and ratings for Cutera and its competitors with MarketBeat's FREE daily newsletter.


Cutera logo

About Cutera

Cutera, Inc. engages in the provision of laser and energy-based aesthetic systems for practitioners. It operates through the following segments: United States, Japan, Asia excluding Japan, Europe, and Rest of the World. Its products include enlighten, excel HR, excel V+, secret Pro, Juliet, secret RF, and xeo. The company was founded by David A. Gollnick in August 1998 and is headquartered in Brisbane, CA.

Headlines

Returns At Cutera (NASDAQ:CUTR) Are On The Way Up
December 6, 2021 |  finance.yahoo.com
Cutera Sees Unusually High Options Volume (NASDAQ:CUTR)
December 3, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:CUTR
Employees
323
Year Founded
1998

Sales & Book Value

Annual Sales
$147.68 million
Book Value
$3.08 per share

Profitability

Net Income
$-23.88 million
Pretax Margin
3.84%

Debt

Price-To-Earnings

Miscellaneous

Free Float
17,580,000
Market Cap
$698.71 million
Optionable
Optionable

Company Calendar

Last Earnings
11/03/2021
Today
12/08/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/16/2022

Social Links


MarketRank

Overall MarketRank

2.31 out of 5 stars

Computer And Technology Sector

265th out of 897 stocks

Electromedical Equipment Industry

6th out of 30 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -












Cutera (NASDAQ:CUTR) Frequently Asked Questions

Is Cutera a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cutera in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cutera stock.
View analyst ratings for Cutera
or view top-rated stocks.

How has Cutera's stock been impacted by COVID-19 (Coronavirus)?

Cutera's stock was trading at $18.11 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CUTR shares have increased by 114.9% and is now trading at $38.91.
View which stocks have been most impacted by COVID-19
.

When is Cutera's next earnings date?

Cutera is scheduled to release its next quarterly earnings announcement on Wednesday, February 16th 2022.
View our earnings forecast for Cutera
.

How were Cutera's earnings last quarter?

Cutera, Inc. (NASDAQ:CUTR) released its quarterly earnings data on Wednesday, November, 3rd. The medical device company reported ($0.08) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.03 by $0.11. The medical device company had revenue of $57.38 million for the quarter, compared to analysts' expectations of $50.90 million. Cutera had a trailing twelve-month return on equity of 15.80% and a net margin of 3.80%. During the same quarter in the prior year, the firm earned ($0.13) EPS.
View Cutera's earnings history
.

What guidance has Cutera issued on next quarter's earnings?

Cutera updated its FY 2021 earnings guidance on Wednesday, November, 17th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $224 million-$228 million, compared to the consensus revenue estimate of $218.82 million.

What price target have analysts set for CUTR?

3 analysts have issued twelve-month price targets for Cutera's stock. Their forecasts range from $60.00 to $65.00. On average, they anticipate Cutera's stock price to reach $61.67 in the next twelve months. This suggests a possible upside of 58.5% from the stock's current price.
View analysts' price targets for Cutera
or view top-rated stocks among Wall Street analysts.

Who are Cutera's key executives?

Cutera's management team includes the following people:
  • David H. Mowry, Chief Executive Officer & Director
  • Rohan Seth, Chief Financial Officer
  • Michael Karavitis, Chief Technology Officer & Executive VP
  • Jeremy Livianu, Secretary, Vice President & General Counsel
  • Anne Werdan, Director-Investor Relations

What is David H. Mowry's approval rating as Cutera's CEO?

1 employees have rated Cutera CEO David H. Mowry on Glassdoor.com. David H. Mowry has an approval rating of 100% among Cutera's employees. This puts David H. Mowry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cutera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cutera investors own include NVIDIA (NVDA), QUALCOMM (QCOM), AbbVie (ABBV), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), DocuSign (DOCU), Pfizer (PFE), Square (SQ) and Twilio (TWLO).

What is Cutera's stock symbol?

Cutera trades on the NASDAQ under the ticker symbol "CUTR."

Who are Cutera's major shareholders?

Cutera's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (13.85%), RTW Investments LP (7.00%), Gamco Investors INC. ET AL (6.55%), Gabelli Funds LLC (2.56%), Millennium Management LLC (2.37%) and Dimensional Fund Advisors LP (2.21%). Company insiders that own Cutera stock include David H Mowry, J Daniel Plants, Joseph E Whitters, Katherine S Zanotti and Rohan Seth.
View institutional ownership trends for Cutera
.

Which institutional investors are selling Cutera stock?

CUTR stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Bridger Management LLC, Renaissance Technologies LLC, The Manufacturers Life Insurance Company , Paradigm Capital Management Inc. NY, Two Sigma Investments LP, Gabelli Funds LLC, and Gamco Investors INC. ET AL.
View insider buying and selling activity for Cutera
or view top insider-selling stocks.

Which institutional investors are buying Cutera stock?

CUTR stock was bought by a variety of institutional investors in the last quarter, including RTW Investments LP, Millennium Management LLC, Russell Investments Group Ltd., Calamos Advisors LLC, Lisanti Capital Growth LLC, Jetstream Capital LLC, Geode Capital Management LLC, and Cinctive Capital Management LP. Company insiders that have bought Cutera stock in the last two years include David H Mowry, J Daniel Plants, Joseph E Whitters, Katherine S Zanotti, and Rohan Seth.
View insider buying and selling activity for Cutera
or or view top insider-buying stocks.

How do I buy shares of Cutera?

Shares of CUTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cutera's stock price today?

One share of CUTR stock can currently be purchased for approximately $38.91.

How much money does Cutera make?

Cutera has a market capitalization of $698.71 million and generates $147.68 million in revenue each year. The medical device company earns $-23.88 million in net income (profit) each year or $0.41 on an earnings per share basis.

How many employees does Cutera have?

Cutera employs 323 workers across the globe.

When was Cutera founded?

Cutera was founded in 1998.

What is Cutera's official website?

The official website for Cutera is www.cutera.com.

Where are Cutera's headquarters?

Cutera is headquartered at 3240 BAYSHORE BOULEVARD, BRISBANE CA, 94005.

How can I contact Cutera?

Cutera's mailing address is 3240 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The medical device company can be reached via phone at (415) 657-5500, via email at [email protected], or via fax at 415-330-2444.


This page was last updated on 12/8/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.